These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36991493)

  • 1. Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema.
    El Rayes EN; Leila M
    Int J Retina Vitreous; 2023 Mar; 9(1):20. PubMed ID: 36991493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
    Schmit-Eilenberger VK
    Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
    McCluskey JD; Kaufman PL; Wynne K; Lewis G
    Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
    [No Abstract]   [Full Text] [Related]  

  • 5. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
    Panos GD; Arruti N; Patra S
    Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy.
    Lima-Fontes M; Leuzinger-Dias M; Barros-Pereira R; Fernandes V; Falcão M; Falcão-Reis F; Rocha-Sousa A; Alves-Faria P
    Ophthalmol Ther; 2023 Feb; 12(1):377-388. PubMed ID: 36417092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
    Mathis T; Papegaey M; Ricard C; Rezkallah A; Matonti F; Sudhalkar A; Vartin C; Dot C; Kodjikian L
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema.
    Elaraoud I; Attawan A; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):95-104. PubMed ID: 26885863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy: The ILUvien in Postoperative CYstoid Macular eDema study.
    Motloch K; Soler V; Delyfer MN; Vasseur V; Wolff B; Issa M; Dot C; Massé H; Weber M; Comet A; Hitzl W; Matonti F; Creuzot-Garcher C; Tadayoni R; Kodjikian L; Couturier A
    Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39004282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intravitreal Fluocinolone Acetonide microimplant (ILUVIEN
    Pacella F; Pacella E; Trovato Battagliola E; Malvasi M; Scalinci SZ; Turchetti P; Salducci M; Lucchino L; Arrico L
    Eur J Ophthalmol; 2021 May; ():11206721211020203. PubMed ID: 34030511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data.
    Avogaro F; Florido A; Calandri A; Toja F; Vingolo EM
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):1759-1766. PubMed ID: 36930491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema.
    Weber LF; Marx S; Auffarth GU; Scheuerle AF; Tandogan T; Mayer C; Khoramnia R
    J Ophthalmic Inflamm Infect; 2019 Jan; 9(1):3. PubMed ID: 30694420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
    Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
    Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.
    Soares RM; Ferreira CC; Fernandes JDS; Madeira C; Silva LMA; Saraiva E; Ribeiro L; Fonseca S
    Clin Ophthalmol; 2024; 18():1057-1066. PubMed ID: 38646183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up.
    Elaraoud I; Quhill H; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):105-9. PubMed ID: 27116231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
    Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
    Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema.
    Zakaria YG; Salman AG; Said AMA; Abdelatif MK
    Clin Ophthalmol; 2022; 16():733-746. PubMed ID: 35300032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.